SRRK - Scholar Rock Holding Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Scholar Rock Holding Corporation

620 Memorial Drive
2nd Floor
Cambridge, MA 02139
United States
857-259-3860
http://www.scholarrock.com

Sector
Industry
Full Time Employees65

Key Executives

NameTitlePayExercisedYear Born
Dr. Nagesh K. Mahanthappa Ph.D., MBAPres, CEO & Exec. DirectorN/AN/A1965
Ms. Erin MooreSr. VP of Fin. & Interim Principal Accounting OfficerN/AN/AN/A
Dr. Alan J. BucklerChief Scientific OfficerN/AN/A1960
Ms. Catherine HuExec. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Junlin HoVP & Head of Corp. LegalN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy. The company is also developing SRK-181, an inhibitor of the activation of transforming growth factor beta-1 to treat cancers resistant to checkpoint blockade therapies. In addition, it is developing a pipeline of novel product candidates for a range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Scholar Rock Holding Corporation’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.